ViroPharma Incorporated Reports First Quarter 2008 Financi... ( EXTON Pa. April 30 /- ViroPharma ...)

ViroPharma Incorporated Reports First Quarter 2008 Financial Results

Date:4/30/2008

EXTON, Pa., April 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the first quarter ended March 31, 2008.

Key events since December 31, 2007 include:

Development:

-- Notified sites participating in Phase 3 study of Camvia(TM) (maribavir)

in stem cell transplant patients that enrollment will be complete by

the end of May 2008;

-- Patient enrollment continued in Phase 3 study of maribavir in solid

organ transplant patients;

-- Prelaunch activities for maribavir accelerated in preparation for

planned 2009 initial NDA and MAA filing for maribavir in stem cell

transplant patients;

-- Announced in April that we have discontinued the development of HCV-796

due to the previously announced safety issue that emerged in the

ongoing Phase 2 trial in patients with hepatitis C; and

-- Efforts continued to optimize manufacturing and scale up for non-

toxigenic C. difficile (NTCD) program;

Operational:

-- Vincent J. Milano succeeded Michel de Rosen as president and chief

executive officer;

-- Daniel B. Soland appointed chief operating officer;

-- Net sales of Vancocin(R) achieved $51 million;

-- Vancocin direct sales efforts commenced; and

-- Research and development expenses increased by 171 percent over the

first quarter of 2007, primarily driven by investments in maribavir,

NTCD and increased personnel to support clinical development and

regulatory requirements;

Financial Results:

-- Operating income was $20 million;

-- Increased working capital by $25 million to $619 million;<
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
11. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results

Post Your Comments:

ViroPharma Incorporated Reports First Quarter 2008 Financi...( EXTON Pa. April 30 /- ViroPharma ...),Health